Recent advances need to be highlighted in the management of both localized and metastatic prostate cancer.
New early detection and molecular characterization tools are being developed to improve differentiation of their progression profiles and reduce "overdetection" and "overtreatment" of clinically "insignificant" cancers. In addition, the development of multi-parametric MR has improved the characterization of localized cancer and introduced the new concept of focal treatment. Finally, several treatments for metastatic cancer which is resistant to castration have recently increased the therapeutic armamentarium.
Written by:
Barry Delongchamps N. Are you the author?
Urology Department, Cochin Hospital, 27, rue du Faubourg Saint-Jacques, 75679 Paris cedex 14, France.
Reference: Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):739-42.
doi: 10.1016/j.diii.2014.06.005
PubMed Abstract
PMID: 25052225
UroToday.com Prostate Cancer Section
